Methylphenidate

Methylphenidate, the active ingredient in Methylphenidate, is a central nervous system stimulant presented as an oral dosage form for oral use. It is prescribed for attention deficit hyperactivity disorder and narcolepsy, helping to improve focus and reduce excessive daytime sleepiness.

GNH USA supplies Methylphenidate as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Methylphenidate acts on central nervous system pathways that regulate attention and wakefulness.

- Attention deficit hyperactivity disorder (children and adolescents): improves attention and reduces hyperactivity. - Attention deficit hyperactivity disorder (adults): enhances focus and executive function. - Narcolepsy: decreases daytime sleepiness and improves wakefulness.

Methylphenidate may cause a range of adverse reactions, from mild to severe.

Common Side Effects: - Insomnia: difficulty falling or staying asleep. - Appetite loss: reduced desire to eat. - Headache: mild to moderate pain. - Dry mouth: sensation of oral dryness. - Increased heart rate: mild tachycardia. - Nervousness: feelings of anxiety or jitteriness.

Serious or Rare Side Effects: - Cardiovascular events: chest pain, hypertension, or arrhythmia. - Psychiatric symptoms: hallucinations, mania, or severe anxiety. - Growth suppression: reduced height velocity in children. - Allergic reactions: rash, itching, or swelling. - Priapism: prolonged painful erection. - Seizures: new‑onset convulsions.

Before prescribing methylphenidate, clinicians should evaluate patient history and monitor for potential risks.

- Cardiovascular assessment: review heart disease, hypertension, or arrhythmias. - Psychiatric evaluation: assess for anxiety, bipolar disorder, or psychosis. - Growth monitoring: track height and weight in pediatric patients. - Substance abuse screening: consider risk of misuse or dependence. - Drug interaction review: check concomitant medications that affect catecholamine pathways. - Store at ambient temperature: keep below 25°C in the original container, protect from moisture and direct sunlight.

Methylphenidate can interact with several drug classes, requiring careful management.

Major Interactions (Avoid): - Monoamine oxidase inhibitors (MAOIs): risk of hypertensive crisis. - Sympathomimetic agents: excessive cardiovascular stimulation. - Tricyclic antidepressants: heightened pressor effects.

Moderate Interactions (Monitor Closely): - Antihypertensives: possible reduction in blood‑pressure control. - Anticonvulsants (e.g., carbamazepine): may lower methylphenidate levels. - Proton‑pump inhibitors: potential increase in methylphenidate exposure.